[go: up one dir, main page]

MX2018007458A - Composiciones de benzofenonas polihidroxiladas y metodos para el tratamiento de trastornos neurodegenerativos. - Google Patents

Composiciones de benzofenonas polihidroxiladas y metodos para el tratamiento de trastornos neurodegenerativos.

Info

Publication number
MX2018007458A
MX2018007458A MX2018007458A MX2018007458A MX2018007458A MX 2018007458 A MX2018007458 A MX 2018007458A MX 2018007458 A MX2018007458 A MX 2018007458A MX 2018007458 A MX2018007458 A MX 2018007458A MX 2018007458 A MX2018007458 A MX 2018007458A
Authority
MX
Mexico
Prior art keywords
treatment
compositions
methods
neurodegenerative disorders
polyhydroxylated
Prior art date
Application number
MX2018007458A
Other languages
English (en)
Inventor
Huei TSAI Li-
J Haggarty Stephen
Patnaik Debasis
Chieh Pao Ping-
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2018007458A publication Critical patent/MX2018007458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/34—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de benzofenona polihidroxilada útiles en el tratamiento de enfermedades neurodegenerativas, neurológicas, psiquiátrica y cognitivas, en particular las asociadas con una deficiencia en la actividad de desacetilasa HDAC1.
MX2018007458A 2015-12-17 2016-12-19 Composiciones de benzofenonas polihidroxiladas y metodos para el tratamiento de trastornos neurodegenerativos. MX2018007458A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268899P 2015-12-17 2015-12-17
PCT/US2016/067592 WO2017106861A1 (en) 2015-12-17 2016-12-19 Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2018007458A true MX2018007458A (es) 2018-11-29

Family

ID=59057697

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007458A MX2018007458A (es) 2015-12-17 2016-12-19 Composiciones de benzofenonas polihidroxiladas y metodos para el tratamiento de trastornos neurodegenerativos.

Country Status (13)

Country Link
US (2) US11180438B2 (es)
EP (1) EP3390347A4 (es)
JP (1) JP2019504827A (es)
KR (1) KR20180101404A (es)
CN (1) CN109071417A (es)
AU (1) AU2016369642A1 (es)
BR (1) BR112018012343A2 (es)
CA (1) CA3008854A1 (es)
CL (1) CL2018001633A1 (es)
IL (1) IL260046A (es)
MX (1) MX2018007458A (es)
RU (1) RU2018126187A (es)
WO (1) WO2017106861A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111393277B (zh) * 2020-03-15 2023-01-03 山西医科大学 4-丁基多羟基二苯甲酮类化合物衍生物及其应用
CN119193468A (zh) * 2024-09-26 2024-12-27 北京大学第三医院（北京大学第三临床医学院） 依昔苯酮在制备改善人类早期胚胎发育阻滞的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257272B1 (es) * 1974-01-15 1978-08-25 Pharmascience Labo
DE3877331T2 (de) * 1987-11-11 1993-05-27 Pharmascience Lab Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung.
JPH02206A (ja) * 1987-11-11 1990-01-05 Fujisawa Pharmaceut Co Ltd エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6777578B2 (en) 2000-04-27 2004-08-17 Arizona Board Of Regents Hydroxyphenstatin and the prodrugs thereof
GB0724989D0 (en) * 2007-12-21 2008-01-30 Univ Sheffield Novel compounds
AU2009274571A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (HDAC1) protects against DNA damage and increases neuronal survival
CA2834548C (en) * 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
PT2734510T (pt) * 2011-07-22 2019-02-13 Massachusetts Inst Technology Ativadores de histona desacetilases de classe i (hdacs) e seus usos
US9862746B2 (en) * 2013-02-15 2018-01-09 The Regents Of The University Of Michigan Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
WO2015054474A1 (en) * 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors

Also Published As

Publication number Publication date
US20200087236A9 (en) 2020-03-19
CA3008854A1 (en) 2017-06-22
AU2016369642A1 (en) 2018-08-02
RU2018126187A (ru) 2020-01-20
KR20180101404A (ko) 2018-09-12
EP3390347A1 (en) 2018-10-24
US11180438B2 (en) 2021-11-23
JP2019504827A (ja) 2019-02-21
CN109071417A (zh) 2018-12-21
BR112018012343A2 (pt) 2018-12-04
US20180290960A1 (en) 2018-10-11
CL2018001633A1 (es) 2019-01-18
WO2017106861A1 (en) 2017-06-22
EP3390347A4 (en) 2019-07-24
US11639325B2 (en) 2023-05-02
IL260046A (en) 2018-07-31
US20210171429A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
SA520411187B1 (ar) نظائر فينيل ألانينول كربامويل واستخداماتها
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MX380147B (es) Formas de dosificacion de ruxolitinib de liberacion sostenida.
PH12016500862A1 (en) Autotaxin inhibitor compounds
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
TN2014000326A1 (en) Inhibitors of beta-secretase
NZ783466A (en) Compositions comprising 15-hepe and methods of using the same
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2016006633A (es) Uso de hidroxamatos de indolilo e indolinilo para tratar trastornos neurodegenerativos o deficiencias cognitivas.
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MD20150030A2 (ro) Inhibitori de beta-secretază
MX2019003725A (es) Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
PH12016501938A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2018007458A (es) Composiciones de benzofenonas polihidroxiladas y metodos para el tratamiento de trastornos neurodegenerativos.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2016015767A (es) Compuestos para el tratamiento de convulsiones y otros trastornos y condiciones del sistema nervioso central.
PH12020500472A1 (en) Autotaxin inhibitor compounds
IN2013MU03429A (es)